SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMMULOGIC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rob who wrote (126)3/7/1997 12:54:00 PM
From: David Bleich   of 305
 
I disagree with your friends analysis of the most recent data on the Ragweed vaccine. IMUL conducted a double blinded study and demonstrated a 19% reduction in symptom score when comparing the Ragweed vaccine with placebo. This was statistically significant with p<.04. In addition the symptom score was reduced by ~40% when compared to a non-placebo control group. These results tell us two important facts: 1. the placebo effect is as significant as the actual drug effect (I expect this data would be similar in any allergy study) and 2. the likelihood of the 19% reduction in symptom score happening by chance is 4 out of 100. Therefore, IMUL's data is strong. No one argues that the drug really produces an effect. Remember most drugs do not give even a 50% improvement in the endpoint studied. Also a symptom score is different from blood pressure or another biochemical parameter in that it is a subjective symptom and not an objective measurement. As far as Genentech's IgE vaccine is concerned, this will not be competitioin at all. In fact it is likely that a combination of the two vaccines may be more effective than a single therapy. Allergy is a very complex mechanism involving IgE, histamine, cytokines, T-lymphocytes, and a host other immune factors. Therefore, there should be multiple sites of attack in blocking the immune response. I envision both therapies have a significant benefit to clinical allergy sufferers. However, IMUL will be there first.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News